Immunomedicals shares are trading higher after B of A Securities maintained a Buy rating on the company's stock and raised its price target from $45 to $47.
Benzinga · 5小时前
2 “Strong Buy” Healthcare Stocks That Could Be the Next M&A Target
Which stocks have been the stars of 2020? Biotechs. Amid the onset of the global health crisis, companies advancing COVID-19 vaccines, treatments and testing kits have seen their shares take off rapidly on an upward trajectory. That said, Wall Street focus has
TipRanks · 5天前
Biotech Bonanza - Second Half Outlook
Seeking Alpha · 6天前
4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront
MotleyFool.com · 6天前
AstraZeneca Inks Multibillion-Dollar Cancer Treatment Collaboration
AstraZeneca on Monday unveiled a cancer treatment partnership with a Japanese company that could be worth as much as $6 billion and aims for best-in-class treatment of lung and other cancer.
Investor's Business Daily · 07/27 20:10
Immunomedics Analyst Says Trodelvy Likely To Capture 50% Market Share
Immunomedics, Inc. (NASDAQ: IMMU) stock, which has been on a broader upward trajectory since FDA approved its lead asset Trodelvy, has further room to run, according to a Jefferies analyst. The Immunomedics Analyst: Chris Howerton reiterated a Buy rating on I
Benzinga · 07/27 18:23
Immunomedics shares are trading higher after Jefferies Maintained its Buy rating on the stock and raised its price target from $41 to $55 per share.
Benzinga · 07/27 12:51
Immunomedics to Report Second Quarter 2020 Results and Host Conference Call and Webcast on August 5, 2020
MORRIS PLAINS, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that it will host a conference call on Wedn